By comparing the expression of GOT2 in normal B cells and different B-cell lymphomas, Feist et al. determined that abnormal GOT2 expression was characteristic of a subgroup of DLBCL. This evidence concerns the gene GOT2 and B-cell non-Hodgkin lymphoma.